Key facts
- Persperion Diagnostics’s last known valuation is $13.0M (Jun 2023).
- It has raised $4.5M across 2 recorded rounds; the latest was Seed Round ($4.0M) in Jun 2023.
- Notable investors include Samsung NEXT Ventures, Miracleplus, University of California, CONNECT (San Diego), Foothill Ventures — 10 tracked in total.
- Persperion Diagnostics has filed 3 Form Ds with the SEC since 2023, most recently May 2025 ($450K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Persperion Diagnostics
Funding rounds
2 roundsAbout Persperion Diagnostics
Operator of a medical device company intended to develop a novel non-invasive sweat biomarker sensing technology. The company aims to reimagine personalized health management using natural fingertip sweat and develops a touch-based enzymatic electrochemical sensing strip, enabling patients to sense different biomarkers within natural fingertip perspiration.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2022
- Employees
- 13
- Website
- persperiontech.com/
- Ownership
- Privately Held (backing)
Persperion Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Persperion Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Persperion Diagnostics in its N-PORT filings yet. We sweep new filings monthly.